September 18, 2025 — Las Vegas, Nevada Avant Technologies and Austrianova have entered into a Joint Venture and Licensing Agreement to form Klothonova, Inc., a Nevada-based company dedicated to advancing Klotho-based cell therapies. The collaboration combines Austrianova’s proprietary cell encapsulation technology with Avant’s capital and resources to develop treatments for Alzheimer’s disease, cancer, kidney disease, heart disease, and other age-related conditions. The goal is to pioneer longevity-enhancing solutions using encapsulated Klotho-producing cells.
Science Significance
The Klotho protein, discovered in 1997, is known as an anti-aging protein due to its role in modulating aging processes and supporting vital functions in the kidneys and brain. It has been linked to improved cognitive performance, cardiovascular health, and renal function. By combining Klotho with advanced cell encapsulation, Klothonova aims to create durable, regenerative therapies that protect healthy cells while enhancing the delivery of therapeutic proteins. This approach positions the joint venture at the forefront of cell-based therapeutics and regenerative medicine.
Regulatory Significance
The formation of Klothonova is strategically timed with increasing global regulatory support for cell-based therapies and gene-based technologies. Agencies across the U.S., Europe, and Asia are building frameworks for novel biologics and cell therapies, including fast-track approvals and orphan drug incentives. Establishing a licensed joint venture strengthens the intellectual property position and provides a platform for securing regulatory designations, enabling smoother pathways for clinical development and eventual commercialization.
Business Significance
Advertisement
By creating Klothonova as a 50/50 joint venture, Avant and Austrianova share both risk and opportunity. Austrianova contributes its patented encapsulation technology, GMP-grade expertise, and scientific know-how, while Avant provides funding and operational support. This balance positions the company to accelerate market entry for multiple therapeutic programs. The collaboration also enhances long-term business resilience, improves the ability to attract investment, and sets the stage for global partnerships in the competitive biopharma industry.
Patients’ Significance
For patients, the therapies under development hold the potential to transform treatment for age-related diseases that currently rely on symptom management. Conditions like Alzheimer’s, cardiovascular disease, and chronic kidney disease have limited curative options. Encapsulated Klotho-based therapies could slow disease progression, restore cellular balance, and extend healthy lifespan. Patients would benefit from minimally invasive treatments, reduced side effects, and therapies designed to improve not just survival but overall quality of life and longevity.
Policy Significance
The launch of Klothonova highlights the growing importance of public policy in biotechnology innovation. Governments worldwide are promoting healthy aging initiatives and encouraging private-public collaborations to reduce the economic burden of chronic and age-related diseases. Policies supporting research funding, patent protections, and regulatory incentives are essential to ensure equitable access to new therapies. This partnership aligns with broader health strategies aimed at addressing the global challenge of aging populations.
The establishment of Klothonova, Inc. through the collaboration of Avant Technologies and Austrianova marks a pivotal moment in the pursuit of regenerative medicine and longevity research. With a mission to develop Klotho-based cell therapies, the joint venture brings together scientific innovation, regulatory opportunity, business strength, patient impact, and policy alignment. As programs advance toward clinical testing, Klothonova has the potential to redefine how age-related diseases are treated, shaping the future of healthcare and extending the promise of healthier, longer lives.
Source: Avant Technologies Inc. Press Release
